EUVIMEDEUVIMED entdecken
MetaanalyseÜbersichtsarbeitOpen Access · CC BY 4.0

Efficacy and safety of fostamatinib in refractory immune thrombocytopenia: a meta-analysis from randomized controlled trials

Songphol Tungjitviboonkun, Naharuthai Bumrungratanayos, Jedsadakorn Jitwimungsanon, Thanat Kheamakulvanich, Smuch Siramongkholkarn

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-05824-7 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Annals of Hematology, 2024. Verfasst von Songphol Tungjitviboonkun und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of California San Francisco, San Francisco, United States. Songphol157@gmail.com. Hauptthemen laut MEDLINE: Aminopyridines, Morpholines, Oxazines, Purpura, Thrombocytopenic, Idiopathic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune thrombocytopenia (ITP) is an immune-mediated disease that results in low platelet counts. Despite appropriate treatment, many patients continue to experience refractory disease. Fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, has emerged as a promising option for refractory ITP.

Objective

This meta-analysis aims to evaluate the efficacy and safety of fostamatinib compared to conventional therapy in adults aged ≥ 18 years with refractory ITP. Materials and methods Literature search was conducted in PubMed, Scopus, Embase, and clinicaltrials.gov databases from inception to March 31, 2024. Randomized controlled trials (RCTs) assessing the safety and efficacy of fostamatinib in adults with refractory ITP were included. Data extraction, risk of bias assessment, and statistical analysis were performed following PRISMA guideline.

Results

A total of 495 articles were screened, with three RCTs meeting the inclusion criteria. Fostamatinib therapy demonstrated superior efficacy in achieving stable platelet response by week 24 (ORR 0.80; 95%CI 0.72–0.88), platelet count ≥ 50,000/µL at weeks 12 (ORR 0.80; 95%CI 0.72–0.90) and week 24 (ORR 0.82; 95%CI 0.72–0.90). Additionally, fostamatinib improves platelet counts in subjects with a baseline count of < 15,000/µL. The Number Needed to Treat (NNT) was calculated as 10. Adverse effects include diarrhea (RR 2.32; 95%CI 1.11–4.84), hypertension (RR 2.33; 95%CI 1.00-5.43), and abnormal liver function tests (RR 4.18; 95% CI 1.00-17.48). Interestingly, the occurrences of nausea (RR 1.77; 95% CI 0.33–9.67) and rash (RR 2.28; 95% CI 0.50-10.29) did not achieve statistical significance.

Conclusion

This meta-analysis provides robust evidence supporting the efficacy of fostamatinib in improving platelet counts and achieving therapeutic goals in adults with refractory ITP. However, fostamatinib’s safety profile warrants consideration due to higher rates of diarrhea, hypertension, and abnormal liver function tests.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminopyridinesMorpholinesOxazinesPurpura, Thrombocytopenic, IdiopathicPyridinesPyrimidinesAdultHumansPlatelet CountProtein Kinase InhibitorsRandomized Controlled Trials as TopicSyk KinaseTreatment Outcome

Stichwörter der Autor:innen

FostamatinibITPImmune thrombocytopeniaMeta-analysisRefractory ITPSYK inhibitorSpleen tyrosine kinase

Substanzen

AminopyridinesfostamatinibMorpholinesOxazinesProtein Kinase InhibitorsPyridinesPyrimidinesSyk Kinase

Autor:innen und Institutionen

  • University of California San Francisco, San Francisco, United States. Songphol157@gmail.com.
  • Division of Hematology, Department of Medicine, Sirindhorn Hospital, Bangkok, Thailand. Songphol157@gmail.com.
  • HRH Princess Maha Chakri Sirindhorn Medical Center, Faculty of Medicine, Srinakharinwirot University, Nakhon Nayok, Thailand.
  • Division of Hematology, Department of Medicine, Sirindhorn Hospital, Bangkok, Thailand.
  • Koh Sichang Hospital, Chonburi, Thailand.
  • Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Zitieren

APA

Tungjitviboonkun, S., Bumrungratanayos, N., Jitwimungsanon, J., Kheamakulvanich, T., & Siramongkholkarn, S. (2024). Efficacy and safety of fostamatinib in refractory immune thrombocytopenia: a meta-analysis from randomized controlled trials. Annals of Hematology. https://doi.org/10.1007/s00277-024-05824-7

Vancouver

Tungjitviboonkun S, Bumrungratanayos N, Jitwimungsanon J, Kheamakulvanich T, Siramongkholkarn S. Efficacy and safety of fostamatinib in refractory immune thrombocytopenia: a meta-analysis from randomized controlled trials. Annals of Hematology. 2024. doi:10.1007/s00277-024-05824-7

BibTeX
@article{Tungjitviboonkun2024,
  author = {Tungjitviboonkun, Songphol and Bumrungratanayos, Naharuthai and Jitwimungsanon, Jedsadakorn and Kheamakulvanich, Thanat and Siramongkholkarn, Smuch},
  title = {Efficacy and safety of fostamatinib in refractory immune thrombocytopenia: a meta-analysis from randomized controlled trials},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-05824-7}
}
Kostenlos starten →